The rapid transmission of viral diseases can cause massive economic damage and loss of life. The manufacture of most anti-viral drugs is normally carried out using batch synthesis which typically requires long production times (3–15 days) and significant manpower and infrastructure. The fabrication of fully integrated flow-based manufacturing systems offers an alternative approach that can be greener and more economical. In this regard, we have developed a compact manufacturing machine for the synthesis of the antiviral API daclatasvir which is easily reconfigured, has a much-reduced footprint, and enables multi-step synthesis using innovative reaction chemistry and post-synthesis purification equipment. The developed integrated system enabled the ultra-fast production of DCV as its free base (within 28.2 min.) with a throughput of 11.8 g per day (equivalent to 200 doses of Daklinza, 60 mg tablets) in 98% HPLC purity.

中文翻译：

---

daclatasvir的集成多步连续流合成，无需中间纯化和溶剂交换

病毒性疾病的快速传播会造成巨大的经济损失和生命损失。大多数抗病毒药物的生产通常使用批量合成法进行，这通常需要较长的生产时间（3-15天）以及大量的人力和基础设施。完全集成的基于流程的制造系统的制造提供了一种更环保，更经济的替代方法。在这方面，我们已经开发了一种紧凑的制造机器，用于合成抗病毒API达卡他韦，该机器易于重新配置，占地面积大大减少，并且可以使用创新的反应化学和合成后的纯化设备进行多步合成。所开发的集成系统使DCV超快生产成为其免费产品（28.2分钟内），吞吐量为11。